Covid 19 Research using Clinical Trials (Home Page)
Aluminum hydroxideWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
Correlated MeSH Terms (1)
|
Name (Synonyms) |
Correlation |
D018352 | Coronavirus Infections NIH | 0.04 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
Severe acute respiratory syndrome (SARS) is a viral illness that affects the respiratory
(breathing) system. The purpose of this study is to evaluate the safety and protective
(immune) responses to different doses of a SARS vaccine given with or without an adjuvant. An
adjuvant is a substance that may be added to a vaccine to improve the immune response so that
less of the vaccine may need to be given. Study participants will include 72 volunteers, ages
18-40, living in the Houston, Texas area. The study will take place at Baylor College of
Medicine. Participants will receive 2 injections of vaccine or placebo (substance made to
look like the study vaccine but contains no medication) given 1 month apart. Participants
will fill out a memory aid (diary) to document daily temperature and illness signs and
symptoms for 7-9 days after each injection. During the 9 study visits, several blood samples
will be collected. Participants will be in the study for up to 211 days, including screening.
NCT00533741 Coronavirus (SARS-CoV) Drug: Aluminum hydroxide Drug: Placebo Biological: SARS-CoV
Primary Outcomes
Measure: Frequency and description of serious adverse events (SAEs). Time: 5 months after receipt of the booster dose of vaccine.
Measure: Frequency of significant increases in serum antibody to CoV S protein in Enzyme Linked Immunosorbent Assay (ELISA) and in neutralization tests, and increases in Geometric Mean Titers (GMT)s in sera. Time: Screening, 1 and 5 months after the booster dose of vaccine.
Measure: Frequency and severity of solicited injection site and systemic signs and symptoms and unsolicited adverse events (AE) / SAEs. Time: 1 month after receipt of the first and second doses of vaccine.
Secondary Outcomes
Measure: Frequency of significant serum antibody increases and increases in Geometric Mean Titers (GMT)s, as measured in neutralizing antibody tests and an ELISA against SARS-CoV S protein. Time: Collected just before the first vaccination and at 1 month (just before booster).
No related HPO nodes (Using clinical trials)